Valuation: Cocrystal Pharma, Inc.

Market Cap 14.06M 12.33M 11.37M 10.64M 19.95M 1.33B 20.37M 137M 52.86M 656M 52.81M 51.65M 2.27B P/E 2026 *
-1.49x
P/E 2027 * -1.59x
Enterprise Value 14.06M 12.33M 11.37M 10.64M 19.95M 1.33B 20.37M 137M 52.86M 656M 52.81M 51.65M 2.27B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
69.27%
Yield 2026 *
-
Yield 2027 * -
1 day+0.99%
1 week+2.51%
Current month-8.93%
1 month-11.30%
3 months-5.56%
6 months+4.71%
Current year+4.19%
1 week 0.97
Extreme 0.97
1.08
1 month 0.94
Extreme 0.94
1.2
Current year 0.86
Extreme 0.8588
2.03
1 year 0.86
Extreme 0.8588
2.67
3 years 0.86
Extreme 0.8588
3.28
5 years 0.86
Extreme 0.8588
17.88
10 years 0.86
Extreme 0.8588
205.2
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-02
Chief Executive Officer 59 2021-05-26
Chief Executive Officer 66 2021-05-26
Director TitleAgeSince
Director/Board Member 88 2014-01-01
Chairman 79 2021-05-26
Director/Board Member 65 2014-01-01
Date Insider Type Main position Quantity % Market Cap.
06-02Free

Chief Executive Officer

235,000 1.7044%
02-23Buy

Director

20,000 0.1451%
02-05Buy

Director

50,000 0.3627%
Change 5-day change 1-year change 3-year change Capi.($)
+0.99%+2.51%-32.89%-57.50% 13.93M
+0.33%+2.83%+62.37%+115.97% 55.35B
+0.82%+15.05%+74.28%+86.70% 51.92B
+1.36%+0.36%-12.96%-14.86% 22.76B
-1.04%+7.91%-1.40%+417.94% 22.64B
-0.18%+7.20%+28.56%-12.48% 17.36B
-1.10%+4.61%+29.38%-34.99% 16.1B
-3.35%+8.96%+135.18%+294.38% 13.96B
+2.89%+5.51%+25.82%+175.78% 13.38B
+1.31%+0.53%+27.21% - 12.27B
Average +0.20%+4.31%+33.55%+107.88% 22.57B
Weighted average by Cap. +0.25%+5.29%+46.58%+120.51%

Financials

2026 *2027 *
Net sales - -
Net income -10.5M -9.21M -8.49M -7.94M -14.9M -990M -15.21M -102M -39.47M -490M -39.43M -38.57M -1.7B -11.5M -10.08M -9.29M -8.7M -16.32M -1.08B -16.66M -112M -43.23M -536M -43.18M -42.24M -1.86B
Net Debt - -
Logo Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Employees
10
Date Price Change Volume
26-06-26 US$1.020 +0.99% 67,843
26-06-25 US$1.010 -3.81% 97,323
26-06-24 US$1.050 -0.94% 112,112
26-06-23 US$1.060 +6.00% 132,497
26-06-22 US$1.000 +0.50% 104,368
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.020USD
Average target price
9.000USD
Spread / Average Target
+782.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COCP Stock